XML 95 R78.htm IDEA: XBRL DOCUMENT v3.24.2.u1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Nov. 21, 2023
Jun. 26, 2022
Jul. 31, 2021
Dec. 31, 2023
Dec. 31, 2022
Description for advisory agreement     the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023    
Stocked based compensation       $ 577,931 $ 24,401
Payment of additional tax       99,644  
Compensation for non-pecuniary damage amounting       21,744  
General and administrative expenses       164,859  
Four Third Party Consultants [Member]          
Awarded shares 970,000        
Awarded share value $ 999,100        
Phase 1 [Member]          
Project cost   $ 838,450      
Phase 2 [Member]          
Project cost   $ 907,084      
National Medicines Agency [Member] | General and administrative expenses [Member]          
Stocked based compensation       77,250  
Imposed fine       $ 16,214